ProQR Therapeutics NVMEX:PRQRN 44 PS Ratio is 13.25 as of Jun. 26, 2026, which is 23% below its 10-year median of 17.28. GuruFocus rates MEX:PRQRN with a GF Score™ of 44/100 and a GF Value™ of MXN46.47. The stock has 4 warning signs investors should review. Among 936 Biotechnology companies, ProQR Therapeutics NV ranks worse than 53.31% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ProQR Therapeutics NV's share price is MXN36.00.
ProQR Therapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN2.72. Hence, ProQR Therapeutics NV's PS Ratio for today is 13.25.
The historical rank and industry rank for ProQR Therapeutics NV's PS Ratio or its related term are showing as below:
MEX:PRQRN'
s PS Ratio Range Over the Past 10 Years
Min: 4.96 Med: 17.28 Max: 2117.5
Current: 10.57
During the past 13 years, ProQR Therapeutics NV's highest PS Ratio was 2117.50. The lowest was 4.96. And the median was 17.28.
MEX:PRQRN's PS Ratio is ranked worse than 53.31% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs MEX:PRQRN: 10.57
During the past 13 years, ProQR Therapeutics NV's highest 3-Year average Revenue per Share Growth Rate was 115.40% per year. The lowest was 49.50% per year. And the median was 82.45% per year.
Back to Basics: PS Ratio
ProQR Therapeutics NV (MEX:PRQRN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PRQRN vs GALT, HRTX, PLYX: PS Ratio Comparison
For the Biotechnology subindustry, ProQR Therapeutics NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProQR Therapeutics NV PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's PS Ratio distribution charts can be found below:
* The bar in red indicates where ProQR Therapeutics NV's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ProQR Therapeutics NV's Share Price of today is MXN36.00. ProQR Therapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN2.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ProQR Therapeutics NV (MEX:PRQRN) has a PS Ratio of 13.25 as of Jun. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ProQR Therapeutics NV and its competitors. This is 23% below median its historical median of 17.28. Over the past decade, ProQR Therapeutics NV's PS Ratio has ranged from 4.96 to 2,117.50. According to the industry distribution chart, ProQR Therapeutics NV ranks #499 out of 936 companies in the Biotechnology industry, placing it in the top 53.3%.
Is ProQR Therapeutics NV's PS Ratio too high?
ProQR Therapeutics NV's current PS Ratio of 13.25 is 23% below median its 10-year median of 17.28. Over the past 10 years, this metric has ranged from a low of 4.96 to a high of 2,117.50. The Biotechnology industry median PS Ratio is 9.17. ProQR Therapeutics NV's value of 13.25 is 44.6% above this industry median. Based on the distribution chart, ProQR Therapeutics NV ranks #499 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ProQR Therapeutics NV has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's PS Ratio compare to GALT and HRTX?
According to the Biotechnology industry distribution chart, ProQR Therapeutics NV ranks #499 out of 936 companies for PS Ratio. This places ProQR Therapeutics NV in the lower half of its industry. The industry median PS Ratio is 9.17. ProQR Therapeutics NV's value of 13.25 is 44.6% above this benchmark. Historically, ProQR Therapeutics NV's own PS Ratio has ranged from 4.96 to 2,117.50 over the past decade. While the company's 10-year median is 17.28 vs. the industry median of 9.17, ProQR Therapeutics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProQR Therapeutics NV's current PS Ratio of 13.25 is 44.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ProQR Therapeutics NV and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProQR Therapeutics NV's current PS Ratio is 13.25, which is 23% below median its own 10-year median of 17.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current PS Ratio of 13.25. The stock's GF Value™ is MXN46.47, compared to a current price of MXN36.00 — trading 22.5% below its estimated fair value. The current PS Ratio is 13.25, which is 23% below median its 10-year median of 17.28 and 44.6% above the Biotechnology industry median of 9.17. ProQR Therapeutics NV's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current PS Ratio is 13.25 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?
Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued.
The current stock price of MXN36.00 is trading 22.5% below its estimated GF Value™ of MXN46.47.
Key valuation signals for MEX:PRQRN:
PS Ratio: 13.25 (23% below median its 10-year median of 17.28)
GF Value™: MXN46.47 vs. price of MXN36.00 (22.5% below fair value)
Industry Position: 44.6% above the Biotechnology median (#499 of 936)
No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
44GF Score
Get the complete analysis for MEX:PRQRN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PRQRN has been successfully added to your 
